Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011

LYNBROOK, N.Y., Nov. 1, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Tuesday, November 8, 2011 to report its third quarter 2011 financial results and provide a corporate update.

In order to participate in the conference call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at, or you may use the link:

A replay of the call will be available one hour after the end of the conference on November 8, 2011 until 9:00 a.m. EST on November 18, 2011. To access the replay, please dial 877-344-7529 (domestic) or 412-317-0088 (international) and reference the access code 10005920. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease which is currently in Phase 3 pivotal clinical trials, frozen shoulder (Adhesive Capsulitis) and cellulite. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
2. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
4. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
5. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
6. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
7. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
8. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
9. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
10. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
Breaking Biology News(10 mins):